SKAN Group AGFRA:7VG +2.61%66 5-Year Yield-on-Cost % is 0.41 as of Jul. 13, 2026, which is 21% above its 10-year median of 0.34. GuruFocus rates FRA:7VG with a GF Score™ of 66/100 and a GF Value™ of €91.00 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 327 Medical Devices & Instruments companies, SKAN Group AG ranks worse than 89.91% on this metric.
SKAN Group AG's yield on cost for the quarter that ended in Dec. 2025 was 0.41.
The historical rank and industry rank for SKAN Group AG's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:7VG'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.28 Med: 0.34 Max: 0.94
Current: 0.41
During the past 6 years, SKAN Group AG's highest Yield on Cost was 0.94. The lowest was 0.28. And the median was 0.34.
FRA:7VG's 5-Year Yield-on-Cost % is ranked worse than 89.91% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.37
vs FRA:7VG: 0.41
SKAN Group AG (FRA:7VG) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
SKAN Group AG 5-Year Yield-on-Cost % Related Terms
FRA:7VG vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of SKAN Group AG is calculated as
SKAN Group AG (FRA:7VG) has a 5-Year Yield-on-Cost % of 0.41 as of Jul. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on SKAN Group AG and its competitors. This is 21% above median its historical median of 0.34. Over the past decade, SKAN Group AG's 5-Year Yield-on-Cost % has ranged from 0.28 to 0.94. According to the industry distribution chart, SKAN Group AG ranks #294 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is SKAN Group AG's 5-Year Yield-on-Cost % too high?
SKAN Group AG's current 5-Year Yield-on-Cost % of 0.41 is 21% above median its 10-year median of 0.34. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 0.94. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.37. SKAN Group AG's value of 0.41 is 82.7% below this industry median. Based on the distribution chart, SKAN Group AG ranks #294 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SKAN Group AG has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #294 out of 327 companies for 5-Year Yield-on-Cost %. This places SKAN Group AG in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.37. SKAN Group AG's value of 0.41 is 82.7% below this benchmark. Historically, SKAN Group AG's own 5-Year Yield-on-Cost % has ranged from 0.28 to 0.94 over the past decade. While the company's 10-year median is 0.34 vs. the industry median of 2.37, SKAN Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.37, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current 5-Year Yield-on-Cost % of 0.41 is 82.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on SKAN Group AG and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current 5-Year Yield-on-Cost % is 0.41, which is 21% above median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.00, compared to a current price of €59.00 — trading 35.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.41, which is 21% above median its 10-year median of 0.34 and 82.7% below the Medical Devices & Instruments industry median of 2.37. SKAN Group AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current 5-Year Yield-on-Cost % is 0.41 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €59.00 is trading 35.2% below its estimated GF Value™ of €91.00.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
5-Year Yield-on-Cost %: 0.41 (21% above median its 10-year median of 0.34)
GF Value™: €91.00 vs. price of €59.00 (35.2% below fair value)
Industry Position: 82.7% below the Medical Devices & Instruments median (#294 of 327)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
66GF Score
Get the complete analysis for FRA:7VG
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 